VYNE

VYNE Therapeutics Inc.

2.28 USD
+0.06 (+2.70%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

VYNE Therapeutics Inc. stock is up 8.57% since 30 days ago. The next earnings date is May 9, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 42.86% of the previous 6 March’s closed higher than February. 100% of analysts rate it a buy.

About VYNE Therapeutics Inc.

VYNE Therapeutics Inc. focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the. treatment of moderate-to-severe acne vulgaris. FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial. for mild to moderate atopic dermatitis, is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor.